Literature DB >> 25551803

The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.

Frank M Sacks1.   

Abstract

PURPOSE OF REVIEW: To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism RECENT
FINDINGS: ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance. Normolipidemia is sustained by hepatic secretion of VLDL and IDL subspecies that contain both apoE and apoC-III (VLDL E+C-III+). Most of this VLDL E+C-III+ is speedily lipolyzed, reduced in apoC-III content, and cleared from the circulation as apoE containing dense VLDL, IDL, and light LDL. In contrast, in hypertriglyceridemia, most VLDL is secreted with apoC-III but without apoE, and so it is not cleared until it loses apoC-III during lipolysis to dense LDL. In normolipidemia, the liver also secretes IDL and large and medium-size LDL, whereas in hypertriglyceridemia, the liver secretes more dense LDL with and without apoC-III. These pathways establish the hypertriglyceridemic phenotype and link it metabolically to dense LDL. Dietary carbohydrate compared with unsaturated fat suppresses metabolic pathways mediated by apoE that are qualitatively similar to those suppressed in hypertriglyceridemia.
SUMMARY: The opposing actions of apoC-III and apoE on subspecies of VLDL and LDL, and the direct secretion of LDL in several sizes, establish much of the basic structure of human apoB lipoprotein metabolism in normal and hypertriglyceridemic humans.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25551803      PMCID: PMC4371603          DOI: 10.1097/MOL.0000000000000146

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  51 in total

1.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

2.  Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Stephanie E Chiuve; Frank M Sacks
Journal:  Circulation       Date:  2011-10-10       Impact factor: 29.690

3.  Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Frank M Sacks
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

4.  Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.

Authors:  Mark J Graham; Richard G Lee; Thomas A Bell; Wuxia Fu; Adam E Mullick; Veronica J Alexander; Walter Singleton; Nick Viney; Richard Geary; John Su; Brenda F Baker; Jennifer Burkey; Stanley T Crooke; Rosanne M Crooke
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

5.  Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.

Authors:  Shaila P Handattu; Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Vinod K Mishra; Geeta Datta; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-11-02       Impact factor: 5.162

6.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

7.  Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.

Authors:  Carlos O Mendivil; Chunyu Zheng; Jeremy Furtado; Julian Lel; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-12       Impact factor: 8.311

8.  Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond.

Authors:  Avani A Pendse; Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Nobuyo Maeda
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922

9.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

10.  Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Frank M Sacks
Journal:  J Am Heart Assoc       Date:  2013-05-14       Impact factor: 5.501

View more
  47 in total

1.  Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Sarah A Aroner; Jeremy D Furtado; Frank M Sacks; Michael Y Tsai; Kenneth J Mukamal; Robyn L McClelland; Majken K Jensen
Journal:  Diabetologia       Date:  2019-04-04       Impact factor: 10.122

2.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

3.  Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Authors:  Gissette Reyes-Soffer; Carol Sztalryd; Richard B Horenstein; Stephen Holleran; Anastasiya Matveyenko; Tiffany Thomas; Renu Nandakumar; Colleen Ngai; Wahida Karmally; Henry N Ginsberg; Rajasekhar Ramakrishnan; Toni I Pollin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

4.  High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.

Authors:  Majken K Jensen; Sarah A Aroner; Kenneth J Mukamal; Jeremy D Furtado; Wendy S Post; Michael Y Tsai; Anne Tjønneland; Joseph F Polak; Eric B Rimm; Kim Overvad; Robyn L McClelland; Frank M Sacks
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

Review 5.  Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment.

Authors:  Patty W Siri-Tarino; Sally Chiu; Nathalie Bergeron; Ronald M Krauss
Journal:  Annu Rev Nutr       Date:  2015       Impact factor: 11.848

6.  Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.

Authors:  Allyson M Morton; Manja Koch; Carlos O Mendivil; Jeremy D Furtado; Anne Tjønneland; Kim Overvad; Liyun Wang; Majken K Jensen; Frank M Sacks
Journal:  JCI Insight       Date:  2018-02-22

7.  Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates.

Authors:  Andrew A Butler; Jinsong Zhang; Candice A Price; Joseph R Stevens; James L Graham; Kimber L Stanhope; Sarah King; Ronald M Krauss; Andrew A Bremer; Peter J Havel
Journal:  J Biol Chem       Date:  2019-04-15       Impact factor: 5.157

Review 8.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

Review 9.  Sirtuin regulation in aging and injury.

Authors:  Ninu Poulose; Raghavan Raju
Journal:  Biochim Biophys Acta       Date:  2015-08-21

10.  Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Authors:  Julio Alejandro Lamprea-Montealegre; Natalie Staplin; William G Herrington; Richard Haynes; Jonathan Emberson; Colin Baigent; Ian H de Boer
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-12       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.